Serotype emergence and genotype distribution among macrolide-resistant invasive Streptococcus Pneumoniae isolates in the postconjugate vaccine (PCV-7) era

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 743-750

  Liu, Zhenying ^a   Nachamkin, Irving ^a   Edelstein, Paul H ^a   Lautenbach, Ebbing ^a   Metlay, Joshua P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; BACTEREMIA; BACTERIUM CONJUGATION; CONTROLLED STUDY; GENE ISOLATION; GENETIC RESISTANCE; GENOTYPE; HEALTH SURVEY; HUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; PENNSYLVANIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; PREVALENCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84862939198     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05122-11     Document Type: Article

References (26)

1. ABI Biodisk. 2004. Etest technical manual. ABI Biodisk, Solna, Sweden.
2. Austrian R. 1976. The Quellung reaction, a neglected microbiologic technique. Mt. Sinai J. Med. 43:699-709. (Pubitemid 8021485)
3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Edelstein PH. 2004. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. Clin. Infect. Dis. 38(Suppl. 4):S322-S327. (Pubitemid 38669887)
5. Farrell DJ, Couturier C, Hryniewicz W. 2008. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT year 5 (2003-2004). Int. J. Antimicrob. Agents 31:245-249.
6. Farrell DJ, et al. 2003. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother. 47:1777-1783. (Pubitemid 36637795)
7. Farrell DJ, Klugman KP, Pichichero M. 2007. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 26:123-128. (Pubitemid 46183361)
8. Gay K, et al. 2000. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J. Infect. Dis. 182:1417-1424.
9. Harwell JI, Brown RB. 2000. The drug-resistant pneumococcus: clinical relevance, therapy, and prevention. Chest 117:530-541. (Pubitemid 30111608)
10. Hyde TB, et al. 2001. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286:1857-1862. (Pubitemid 33010237)
11. Jenkins SG, Brown SD, Farrell DJ. 2008. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US years 1-4. Ann. Clin. Microbiol. Antimicrob. 7:1.
12. Jenkins SG, Farrell DJ. 2009. Increase in pneumococcus macrolide resistance, United States. Emerg. Infect. Dis. 15:1260-1264.
13. Joloba ML, et al. 2010. Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes. Int. J. Antimicrob. Agents 36:124-128.
14. Jones RN, Jacobs MR, Sader HS. 2010. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int. J. Antimicrob. Agents 36:197-204.
15. Jones RN, Sader HS, Moet GJ, Farrell DJ. 2010. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY antimicrobial surveillance program (1998-2009). Diagn. Microbiol. Infect. Dis. 68:334-336.
16. Lexau CA, et al. 2005. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043-2051. (Pubitemid 41539937)
17. Mandell LA. 2004. Epidemiology and etiology of community-acquired pneumonia. Infect. Dis. Clin. North Am. 18:761-776. (Pubitemid 39536007)
18. McEllistrem MC, Stout JE, Harrison LH. 2000. Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J. Clin. Microbiol. 38:351-353. (Pubitemid 30043315)
19. Metlay JP, et al. 2006. Macrolide resistance in adults with bacteremic pneumococcal pneumonia. Emerg. Infect. Dis. 12:1223-1230.
20. Metlay JP, Lautenbach E, Li Y, Shults J, Edelstein PH. 2010. Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era. Arch. Intern. Med. 170:725-731.
21. Obaro SK. 2002. The new pneumococcal vaccine. Clin. Microbiol. Infect. 8:623-633. (Pubitemid 35277117)
22. Park IH, et al. 2008. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J. Infect. Dis. 198:1818-1822.
23. Sorensen UB. 1993. Typing of pneumococci by using 12 pooled antisera. J. Clin. Microbiol. 31:2097-2100. (Pubitemid 23210500)
24. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566. (Pubitemid 26367644)
25. Tait-Kamradt A, et al. 2000. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob. Agents Chemother. 44:2118-2125. (Pubitemid 30484435)
26. Whitney CG, et al. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746. (Pubitemid 36514704)